Aastrom Biosciences ends drug trial, to cut half its workforce
March 27 (Reuters) - Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia - a form of peripheral arterial disease - and cut about half of its workforce.
The company now plans to focus on its experimental treatment for a heart condition called dilated cardiomyopathy, in which the heart becomes weak and cannot pump blood efficiently.
The company has about 71 employees, according to Thomson Reuters data.
- Body of Korean boy who raised ferry alarm believed found |
- Children's corpses reveal desperate attempts to escape Korean ferry |
- Obama reaffirms commitment to Japan on tour of Asia allies
- UPDATE 2-Body of Korean boy who raised ferry alarm believed found
- U.S. mother, officials settle suit over airport breast milk